Business
BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs
GLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, muscle mass loss, and potential cardiovascular risks. BioRestorative believes its cell-based therapeutic candidates may offer the potential for longer-lasting efficacy with improved safety and dosing advantages. MELVILLE, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innova
About this update from Biorestorative Therapies, Inc.
[{"type":"image","alt":"BioRestorative Therapies, Inc","displaySize":"","headline":null,"caption":"BioRestorative Therapies, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/681a8d8fe6df06a5512b4bdd3f27c992"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XBsy.n130Az83pQRRSvCjg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/681a8d8fe6df06a5512b4bdd3f27c992","width":300,"height":122}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"GLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, muscle mass loss, and potential cardiovascular risks. ","length":151,"tagName":"p"}]},{"val":[{"type":"text","content":"BioRestorative believes its cell-based therapeutic candidates may offer the potential for longer-lasting efficacy with improved safety and dosing advantages.","length":157,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":308,"olType":false},{"type":"text","content":"MELVILLE, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced that IP Australia, the intellectual property branch of the Australian government, has allowed Patent Application No. 2020265664 titled, “Non-naturally occurring three-dimensional (3D) brown adipose-derived stem cell aggregates, and methods of generating and using the same.”","length":535,"tagName":"p"},{"type":"text","content":"The newly allowed patent application provides the broadest protection obtained for BioRestorative’s allogeneic, off-the-shelf, brown adipose-derived stem cell (BADSC) ThermoStem® technology, designed to treat obesity and metabolic disorders. The claims covered are: a method of making a non-naturally occurring three-dimensional brown adipose derived stem cell aggregate.","length":371,"tagName":"p"},{"type":"text","content":"With this allowance, BioRestorative is further protected in its development of potential next-generation, cell-based alternatives to GLP-1 drugs, which continue to be one of the fastest-growing therapeutic categories in the world.","length":230,"tagName":"p"},{"type"...